TOUJEO SOLOSTAR SOLUTION

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

INSULIN GLARGINE

Доступно од:

SANOFI-AVENTIS CANADA INC

АТЦ код:

A10AE04

INN (Међународно име):

INSULIN GLARGINE

Дозирање:

300UNIT

Фармацеутски облик:

SOLUTION

Састав:

INSULIN GLARGINE 300UNIT

Пут администрације:

SUBCUTANEOUS

Јединице у пакету:

3X1.5ML/ 5X1.5ML

Тип рецептора:

Schedule D

Терапеутска област:

INSULINS

Резиме производа:

Active ingredient group (AIG) number: 0147062002; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2015-05-28

Карактеристике производа

_Page 1 of 88 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
TOUJEO
® SOLOSTAR
®
TOUJEO
® DOUBLESTAR
®
Insulin glargine (rDNA origin)
Solution for injection 300 U/mL
Antidiabetic Agent
Long-acting Recombinant Human Insulin Analogue
sanofi-aventis Canada Inc.
2905 Place Louis R.-Renaud
Laval, Quebec H7V 0A3
Date of Initial Approval:
May 28, 2015
Submission Control No: 228382
Date of Revision:
May 12, 2020
_Page 2 of 88 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
DESCRIPTION
.....................................................................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND
PRECAUTIONS....................................................................................
4
ADVERSE REACTIONS
...................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
19
DOSAGE AND ADMINISTRATION
................................................................................
20
OVERDOSAGE
..................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 24
STORAGE AND
STABILITY............................................................................................
27
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
27
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 29
PART II: SCIENTIFIC